These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
64. High-performance liquid chromatography of droperidol in whole blood. Tan ST; Boniface PJ J Chromatogr; 1990 Oct; 532(1):181-6. PubMed ID: 2079533 [No Abstract] [Full Text] [Related]
65. Simultaneous determination of very low concentrations of haloperidol and reduced haloperidol in human serum by a liquid chromatographic method. Vatassery GT; Herzan LA; Dysken MW J Chromatogr; 1988 Dec; 433():312-7. PubMed ID: 3235561 [No Abstract] [Full Text] [Related]
66. The assessment of a psychosocial treatment with chronic schizophrenic patients using neuropsychopharmacological indices. Bütter HJ; Dutil C Prog Neuropsychopharmacol Biol Psychiatry; 1985; 9(5-6):593-7. PubMed ID: 4089185 [TBL] [Abstract][Full Text] [Related]
67. Radioimmunoassay of haloperidol in human serum. Clark BR; Tower BB; Rubin RT Life Sci; 1977 Jan; 20(2):319-25. PubMed ID: 839963 [No Abstract] [Full Text] [Related]
68. [Serum level of perphenazine determines by liquid chromatography]. Dessalles MC; Vienne B; Mahuzier G J Chromatogr; 1989 Jan; 487(1):215-20. PubMed ID: 2715269 [No Abstract] [Full Text] [Related]
69. Measurement of haloperidol in human plasma using reversed-phase high-performance liquid chromatography. Jatlow PI; Miller R; Swigar M J Chromatogr; 1982 Jan; 227(1):233-8. PubMed ID: 7056816 [No Abstract] [Full Text] [Related]
70. High-performance liquid chromatographic determination of haloperidol in plasma. Miyazaki K; Arita T; Oka I; Koyama T; Yamashita I J Chromatogr; 1981 May; 223(2):449-53. PubMed ID: 7251801 [No Abstract] [Full Text] [Related]
72. Haloperidol concentrations in blood in cases of acute intoxication. Coutselinis A; Boukis D; Kentarchou P Clin Chem; 1977 May; 23(5):900. PubMed ID: 852113 [No Abstract] [Full Text] [Related]
73. Automated Interlaboratory Comparison of Therapeutic Drug Monitoring Data and Its Use for Evaluation of Published Therapeutic Reference Ranges. Larsen JB; Hoffmann-Lücke E; Aaslo PH; Jørgensen NR; Greibe E Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36839995 [TBL] [Abstract][Full Text] [Related]
74. Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part II. Miller R Curr Neuropharmacol; 2009 Dec; 7(4):315-30. PubMed ID: 20514211 [TBL] [Abstract][Full Text] [Related]
75. Haloperidol plasma concentration in Japanese psychiatric subjects with gene duplication of CYP2D6. Ohnuma T; Shibata N; Matsubara Y; Arai H Br J Clin Pharmacol; 2003 Sep; 56(3):315-20. PubMed ID: 12919180 [TBL] [Abstract][Full Text] [Related]
76. The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia. Ulrich S; Wurthmann C; Brosz M; Meyer FP Clin Pharmacokinet; 1998 Mar; 34(3):227-63. PubMed ID: 9533984 [TBL] [Abstract][Full Text] [Related]
77. Haloperidol and reduced haloperidol serum levels: correlation with psychopathology in acute schizophrenia. Stevens A; Mahal A; Gaertner HJ Pharmacopsychiatry; 1992 Sep; 25(5):218-23. PubMed ID: 1409866 [TBL] [Abstract][Full Text] [Related]
78. Haloperidol and lorazepam combined: clinical effects and drug plasma levels in the treatment of acute schizophrenic psychosis. Stevens A; Stevens I; Mahal A; Gaertner HJ Pharmacopsychiatry; 1992 Nov; 25(6):273-7. PubMed ID: 1494594 [TBL] [Abstract][Full Text] [Related]
79. Haloperidol: therapeutic window in schizophrenia. Palao DJ; Arauxo A; Brunet M; Bernardo M; Haro JM; Ferrer J; Gonzalez-Monclus E J Clin Psychopharmacol; 1994 Oct; 14(5):303-10. PubMed ID: 7806684 [TBL] [Abstract][Full Text] [Related]